Subscribe To Our Free Newsletter |
Sanofi’s application for new diabetes drug under US FDA review
The NDA submission for lixisenatide is based on results from the GetGoal clinical program1,2 and includes findings from the recently-completed ELIXA study,3 the first completed long-term CV outcomes study of a GLP-1 receptor aganist.